Qin Xuan, Razia Yasmin, Johnson James R, Stapp Jennifer R, Boster Daniel R, Tsosie Treva, Smith Donna L, Braden Christopher R, Gay Kathryn, Angulo Frederick J, Tarr Phillip I
Department of Laboratory Medicine, Children's Hospital and Regional Medical Center, Seattle, WA, USA.
Antimicrob Agents Chemother. 2006 Oct;50(10):3325-9. doi: 10.1128/AAC.00548-06.
The extent to which antibiotic-resistant bacteria are excreted by humans who have not been exposed to antibiotics is not known. Children, who rarely receive fluoroquinolones, provide opportunities to assess the frequency of fecal excretion by fluoroquinolone-naïve hosts of fluoroquinolone-resistant gram-negative bacilli. Fresh nondiarrheal stools from children were processed by screening them on agar containing ciprofloxacin to recover ciprofloxacin-resistant gram-negative bacilli. Resistant isolates were identified, and ciprofloxacin MICs were determined. Resistant Escherichia coli isolates were also analyzed for urovirulence-associated loci. Thirteen (2.9%) of 455 stools yielded ciprofloxacin-resistant E. coli (seven children), Stenotrophomonas maltophilia (four children), and Achromobacter xylosoxidans and Enterobacter aerogenes (one child each). Neither the subjects themselves nor members of their households used fluoroquinolones in the 4 weeks preceding collection. Six of the seven resistant E. coli isolates belonged to phylogenetic groups B2 and D, in which extraintestinal pathogenic E. coli bacteria are frequently found. All resistant E. coli isolates contained at least three putative E. coli virulence loci. Most ciprofloxacin-resistant bacteria were resistant to additional antibiotics. Potentially pathogenic bacteria that are resistant to therapeutically important antimicrobial agents are excreted by some humans, despite these persons' lack of exposure to the particular drugs. The sources of these resistant organisms are unknown. This underrecognized reservoir of drug-resistant potential pathogens poses public health challenges.
未接触过抗生素的人排出耐抗生素细菌的程度尚不清楚。儿童很少接受氟喹诺酮类药物,这为评估未接触过氟喹诺酮类药物的宿主粪便中排出耐氟喹诺酮革兰氏阴性杆菌的频率提供了机会。通过在含环丙沙星的琼脂上筛选儿童的新鲜非腹泻粪便,以回收耐环丙沙星的革兰氏阴性杆菌。鉴定出耐药菌株,并测定环丙沙星的最低抑菌浓度(MIC)。还对耐药大肠埃希菌分离株进行了与尿路致病性相关基因座的分析。455份粪便中有13份(2.9%)检出耐环丙沙星的大肠埃希菌(7名儿童)、嗜麦芽窄食单胞菌(4名儿童)、木糖氧化无色杆菌和产气肠杆菌(各1名儿童)。在采集前4周,受试者本人及其家庭成员均未使用氟喹诺酮类药物。7株耐药大肠埃希菌分离株中有6株属于系统发育组B2和D,肠外致病性大肠埃希菌在这些组中很常见。所有耐药大肠埃希菌分离株至少含有三个假定的大肠埃希菌毒力基因座。大多数耐环丙沙星的细菌对其他抗生素也耐药。尽管有些人未接触过特定药物,但仍有一些人排出对治疗重要抗菌药物耐药的潜在病原菌。这些耐药菌的来源尚不清楚。这种未被充分认识的耐药潜在病原菌库对公共卫生构成了挑战。